NICE approves rituximab for treatment of rare vascular condition

NICE has ruled that rituximab (MabThera) can be considered for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis when used within its marketing authorisation and provided the patient meets certain eligibility criteria.

Rituximab should be available on the NHS for this condition within 3 months of this guidance being issued | SCIENCE PHOTO LIBRARY
Rituximab should be available on the NHS for this condition within 3 months of this guidance being issued | SCIENCE PHOTO LIBRARY

MabThera (rituximab) is licensed for use in combination with glucocorticoids for induction treatment of ANCA-associated vasculitis (defined as severely active granulomatosis with polyangiitis [also known as Wegener's granulomatosis] and microscopic polyangiitis).

To be eligible for treatment with rituximab, the patient must meet one of the following conditions:

  • further treatment with cyclophosphamide would exceed the maximum cumulative dose 
  • cyclophosphamide is contraindicated or not tolerated 
  • the person has not completed their family and cyclophosphamide may affect their fertility
  • the condition has remained active or worsened after a course of cyclophosphamide lasting 3-6 months 
  • the person has had uroepithelial malignancy.

View MabThera drug record

NICE guidance on rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more